{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T09:19:07Z","timestamp":1759483147844},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"S4","license":[{"start":{"date-parts":[[1987,12,1]],"date-time":"1987-12-01T00:00:00Z","timestamp":565315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[1987,12,1]],"date-time":"1987-12-01T00:00:00Z","timestamp":565315200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[1987,12]]},"DOI":"10.1007\/bf00207262","type":"journal-article","created":{"date-parts":[[2004,9,3]],"date-time":"2004-09-03T03:31:46Z","timestamp":1094182306000},"page":"S41-S46","source":"Crossref","is-referenced-by-count":3,"title":["Interferon alfa-2b\/melphalan\/prednisone in previously untreated patients with multiple myeloma: a phase I\u2013II trial"],"prefix":"10.1007","volume":"5","author":[{"given":"M. Robert","family":"Cooper","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Fefer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr","given":"Delvyn C.","family":"Case","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raymond","family":"Kempf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald","family":"Sacher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Neefe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Bickers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Howard","family":"Scarffe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert J.","family":"Spiegel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric M.","family":"Bonnem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"BF00207262_CR1","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1001\/archinte.1975.00330010174022","volume":"135","author":"DE Bergsagel","year":"1975","unstructured":"Bergsagel DE, Phil D, Pruzanski W: Treatment of plasma cell myeloma with cytotoxic agents. Arch Intern Med 135:172\u2013176, 1975","journal-title":"Arch Intern Med"},{"key":"BF00207262_CR2","first-page":"851","volume":"107","author":"DE Bergsagel","year":"1972","unstructured":"Bergsagel DE, Phil D, Cowan DH: Plasma cell myeloma: response of melphalan resistant patients to high dose intermittent cyclophosphamide. Can Med Assoc J 107:851\u2013855, 1972","journal-title":"Can Med Assoc J"},{"key":"BF00207262_CR3","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1200\/JCO.1983.1.8.453","volume":"1","author":"SE Salmon","year":"1983","unstructured":"Salmon SE, Haut A, Bonnet JD: Alternating combination chemotherapy and levamisole improves survival in multiple myeloma: a Southwest Oncology Group study. J Clin Oncol 1:453\u2013461, 1983","journal-title":"J Clin Oncol"},{"key":"BF00207262_CR4","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1200\/JCO.1983.1.8.510","volume":"1","author":"D Bergsagel","year":"1983","unstructured":"Bergsagel D: Progress in the treatment of plasma cell myeloma. J Clin Oncol 1:510\u2013512, 1983","journal-title":"J Clin Oncol"},{"key":"BF00207262_CR5","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/0002-9343(77)90543-5","volume":"63","author":"DC Case Jr","year":"1977","unstructured":"Case DC Jr, Lee BJ, Clarkson BD: Improved survival times in multiple myeloma treated with melphalan, prednisone, cyclophosphamide, vincristine, BCNU: M-2 protocol. Am J Med 63:897\u2013903, 1977","journal-title":"Am J Med"},{"key":"BF00207262_CR6","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/S0140-6736(76)92710-0","volume":"1","author":"DS Alberts","year":"1976","unstructured":"Alberts DS, Durie BG, Salmon SE: Doxorubicin\/BCNU chemotherapy for multiple myeloma in relapse. Lancet 1:926\u2013928, 1976","journal-title":"Lancet"},{"key":"BF00207262_CR7","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1200\/JCO.1985.3.5.654","volume":"3","author":"JJ Costanzi","year":"1985","unstructured":"Costanzi JJ, Cooper MR, Scarffe JH: Phase II study of recombinant alpha-2 interferon in resistant myeloma. J Clin Oncol 3:654\u2013659, 1985","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"BF00207262_CR8","first-page":"183a","volume":"64","author":"JR Quesada","year":"1984","unstructured":"Quesada JR, Alexanian R, Gutterman JU: Induction of remission and restoration of serum immunoglobulins in multiple myeloma with recombinant DNA derived interferon. Blood 64 (Suppl 1):183a, 1984","journal-title":"Blood"},{"key":"BF00207262_CR9","unstructured":"Mellstedt H, Ahre A, Bjorkhom M: Interferon therapy of patients with multiple myeloma. In WD Terry and SA Rosenberg (eds): Elsevier-North Holland Inc., New York, 1982, pp 387\u2013391"},{"key":"BF00207262_CR10","first-page":"5484","volume":"43","author":"YH Tan","year":"1983","unstructured":"Tan YH, Inoue M: Enhancement of actinomycin-D and cis-diamminedichloroplatinum (II) induced killing of human fibroblasts by human beta-interferon. Cancer Res 43:5484\u20135488, 1983","journal-title":"Cancer Res"},{"key":"BF00207262_CR11","first-page":"303","volume":"1","author":"MS Aapro","year":"1981","unstructured":"Aapro MS, Salmon SE, Alberts DS: Schedule dependent synergism of vinblastine and cloned leukocyte interferon A. Stem Cells 1:303\u2013304, 1981","journal-title":"Stem Cells"},{"key":"BF00207262_CR12","first-page":"613","volume":"17","author":"M Tozawa","year":"1982","unstructured":"Tozawa M, Kidowaki T, Terufusa T: Combination therapy of interferon and cyclophosphamide on murine neuroblastoma. J Jpn Soc Cancer Ther 17:613, 1982","journal-title":"J Jpn Soc Cancer Ther"},{"key":"BF00207262_CR13","first-page":"1308","volume":"10","author":"M Namka","year":"1983","unstructured":"Namka M, Yammato S, Tamako H: Potentiation of the cytotoxic effects of various anticancer drugs by interferon on human neoplastic cells (HeLa) in culture. Gan To Kagaku Ryoho 10:1308\u20131312, 1983","journal-title":"Gan To Kagaku Ryoho"},{"key":"BF00207262_CR14","first-page":"904","volume":"44","author":"FR Balkwill","year":"1984","unstructured":"Balkwill FR, Moodie EM: Positive interactions between human interferon and cyclophosphamide or Adriamycin in a human tumor model system. Cancer Res 44:904\u2013908, 1984","journal-title":"Cancer Res"},{"issue":"Suppl 1","key":"BF00207262_CR15","first-page":"188a","volume":"62","author":"RH Clark","year":"1983","unstructured":"Clark RH, Dmitrov NV, Axelson JA: Leucocyte interferon as a biological modification in lymphoproliferative disease. Blood 62 (Suppl 1):188a, 1983","journal-title":"Blood"},{"issue":"Suppl 1","key":"BF00207262_CR16","first-page":"212a","volume":"62","author":"R Ferraresi","year":"1983","unstructured":"Ferraresi R, Rudnick S, Bonnem EM: Enhanced response to chemotherapy after treatment with DNA alpha-2 interferon. Blood 62 (Suppl 1):212a, 1983","journal-title":"Blood"},{"issue":"1","key":"BF00207262_CR17","first-page":"17","volume":"1","author":"Chronic Leukemia-Myeloma Task Force","year":"1968","unstructured":"Chronic Leukemia-Myeloma Task Force. National Cancer Institute. Proposed guidelines for protocol studies II. Plasma cell myeloma. Cancer Chemother Rep Part 3, 1(1):17\u201339, 1968","journal-title":"Cancer Chemother Rep Part 3"},{"key":"BF00207262_CR18","first-page":"38","volume":"3","author":"DS Alberts","year":"1984","unstructured":"Alberts DS, Peng YM, Fisher B: Minimal melphalan systemic availability. A potential cause for failure of adjuvant breast cancer. Proc ASCO 3:38, 1984","journal-title":"Proc ASCO"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00207262.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/BF00207262\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00207262","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00207262.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T17:38:43Z","timestamp":1678556323000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/BF00207262"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1987,12]]},"references-count":18,"journal-issue":{"issue":"S4","published-print":{"date-parts":[[1987,12]]}},"alternative-id":["BF00207262"],"URL":"https:\/\/doi.org\/10.1007\/bf00207262","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[1987,12]]}}}